Colour Online: See the article online to view Figs. 1 and 4 in colour.
LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy
Article first published online: 18 DEC 2012
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
Volume 13, Issue 1, pages 142–152, January 2013
How to Cite
Surin, B., Sachon, E., Rougier, J.-P., Steverlynck, C., Garreau, C., Lelongt, B., Ronco, P. and Piedagnel, R. (2013), LG3 fragment of endorepellin is a possible biomarker of severity in IgA nephropathy. Proteomics, 13: 142–152. doi: 10.1002/pmic.201200267
- Issue published online: 11 JAN 2013
- Article first published online: 18 DEC 2012
- Accepted manuscript online: 17 NOV 2012 05:54AM EST
- Manuscript Accepted: 25 SEP 2012
- Manuscript Revised: 11 SEP 2012
- Manuscript Received: 29 JUN 2012
- Institut National de la Sante et de la Recherche Medicale (INSERM)
- Universite Pierre et Marie Curie (UPMC)
Disclaimer: Supplementary materials have been peer-reviewed but not copyedited.
Table S1. Clinical data of IgAN patients
Table S2. Clinical data of patients with membranous nephropathy
Table S3. Clinical data of patients with diabetic nephropathy
Table S4. Clinical data of patients with lupus nephropathy
Table S5. Clinical data of patients with focal and segmental glomerulosclerosis
Table S6. Clinical data of patients with non-glomerular disease
Figure S1. LG3 spot on 2-DE gels. Spots were visualized by colloidal blue staining. Four replicates for each of the six patients studied were performed and compared to four different controls. Three or four replicates were used for analysis by ImageMaster 2D Platinum, depending on the quality of the gels. Results were summarized on B).
Figure S2a. Peptide mass fingerprint of spot n°1 identified as LG3
Figure S2b. Mascot search result of spot 1 based on MS and MS/MS peptides and ion masses (I)
Figure S2c. Mascot search result of spot 1 based on MS and MS/MS peptides and ion masses (II)
Figure S3. Representative 2-DE Western blot of a healthy control and an IgAN patient. (A) α1-β-glycoprotein; (B) α1-antitrypsin and (C) LG3 fragment.
Figure S4. LG3 level measured by ELISA and normalized with proteinuria, A) or with urine creatinine, B).
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.